tbResList Print — mushTT mushroom Turkey Tail

Filters: qv=306, qv2=%, rfv=%

Product

mushTT mushroom Turkey Tail
Description: <b>Turkey Tail (Trametes versicolor)</b><br>
Key Compounds: Polysaccharide-K (PSK, also known as Krestin) and polysaccharide peptide (PSP).<br>
<br>
-Toll-Like Receptor (TLR) Activation<br>
-Increased NK cell and cytotoxic T-cell activities<br>
-Upregulation of IFN-γ<br>



<p><b>Turkey Tail (Trametes versicolor)</b> — a medicinal polypore mushroom, formerly widely cited as <i>Coriolus versicolor</i>, used as a food-derived medicinal mushroom and source of protein-bound polysaccharides with immunomodulatory activity. It is formally classified here as a food source / medicinal mushroom rather than a single defined drug. Common abbreviations include TV or Tv; its principal standardized derivatives are polysaccharide-K (PSK; Krestin) and polysaccharopeptide (PSP). PSK is a heterogeneous protein-bound β-glucan-rich preparation derived from cultured <i>T. versicolor</i> mycelium, while PSP is a related but compositionally distinct preparation. Clinical evidence applies primarily to standardized PSK rather than to generic Turkey Tail powders or extracts. PSK has been used as an adjunctive cancer therapy in Japan, whereas Turkey Tail and PSK are not FDA-approved cancer treatments in the United States.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Innate immune activation through TLR2-dependent signaling, including activation of dendritic cells and macrophages and increased inflammatory/immune signaling.</li>
<li>Enhancement of adaptive and cytotoxic antitumor immunity, including CD8+ T-cell and NK-cell activity and modulation of cytokines including IFN-γ, TNF-α and IL-2.</li>
<li>Direct antiproliferative and pro-apoptotic effects of selected PSP/PSK-derived preparations in cancer cells, including suppression of NF-κB-associated survival signaling and induction of apoptosis-related transcriptional programs.</li>
<li>Modification of the tumor and host immune environment, including partial reversal of treatment-associated immunosuppression and support of immune surveillance.</li>
<li>Gut microbiome modulation and prebiotic activity from orally administered polysaccharopeptides, potentially contributing to systemic immunomodulation.</li>
<li>ROS and reactive nitrogen signaling as a secondary mechanism: PSP can increase macrophage-derived reactive species, while specific <i>T. versicolor</i> constituents such as laccase can directly increase tumor-cell ROS; this should not be generalized to all Turkey Tail preparations.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> PSK and PSP are heterogeneous, relatively high-molecular-weight protein-polysaccharide mixtures rather than conventional small molecules. Animal radiolabel studies indicate that a fraction of orally administered PSK can be absorbed or distributed beyond the gastrointestinal tract, but much of the dose appears to undergo gastrointestinal degradation or metabolism. Human systemic pharmacokinetic data remain limited. Biological activity after oral administration may therefore reflect gastrointestinal, microbiome and mucosal/immune interactions in addition to direct systemic exposure.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Direct tumor-cell inhibition is often demonstrated using isolated PSP fractions, PSK-related preparations or individual Turkey Tail constituents at concentrations in the tens to hundreds of micrograms per millilitre. Equivalent free systemic concentrations following oral mushroom or PSK administration have not been established in humans and may not be achievable. Direct cytotoxic mechanisms should therefore be considered preclinical and preparation-dependent; immune modulation has substantially stronger biological and clinical plausibility for orally administered PSK.</p>

<p><b>Clinical evidence status:</b> RCT / adjunct use for standardized PSK, with historical randomized studies and meta-analyses reporting improved disease-free or survival outcomes in selected gastric, colorectal and other cancers when PSK was added to contemporaneous chemotherapy. Evidence for whole Turkey Tail mushroom preparations is much weaker and includes small human studies, including a Phase I breast-cancer study showing tolerability and immune effects. A Phase II pilot study of Turkey Tail extract in ER-positive/HER2-negative breast cancer is ongoing. Evidence does not support replacing standard oncologic therapy with Turkey Tail. Product standardization is a major translational limitation because commercially available mushroom powders, mycelial products, PSP and pharmaceutical PSK are not biologically interchangeable.</p>



<h3>Turkey Tail Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TLR2 innate immune activation</td>
<td>Indirect ↓ tumor growth</td>
<td>↑ TLR2 signaling in dendritic cells and macrophages</td>
<td>Immune activation</td>
<td>PSK is a demonstrated TLR2 agonist; this is one of the strongest preparation-specific mechanistic findings.</td>
</tr>
<tr>
<td>2</td>
<td>CD8 T cells and NK cells</td>
<td>↑ immune-mediated killing</td>
<td>↑ cytotoxic lymphocyte activation and function</td>
<td>Enhanced antitumor immune surveillance</td>
<td>PSK antitumor activity in experimental models is substantially dependent on immune-cell activation rather than direct tumor toxicity.</td>
</tr>
<tr>
<td>3</td>
<td>Cytokine immune signaling</td>
<td>Indirect ↓ survival and growth</td>
<td>↑ IFN-γ, TNF-α, IL-2 and other cytokines (preparation-dependent)</td>
<td>Immune potentiation</td>
<td>Magnitude and cytokine profile vary considerably with mushroom strain, extraction method and product composition.</td>
</tr>
<tr>
<td>4</td>
<td>Apoptosis and NF-κB survival signaling</td>
<td>↑ apoptosis; ↓ NF-κB-associated signaling</td>
<td>Comparatively limited cytotoxicity in some experimental models</td>
<td>Direct antiproliferative activity</td>
<td>Best demonstrated for PSP and purified fractions in vitro; relevance to oral systemic exposure is uncertain.</td>
</tr>
<tr>
<td>5</td>
<td>Cell cycle and stress-response signaling</td>
<td>↓ proliferation; ↑ GADD45 and other stress-response programs</td>
<td>Not well characterized</td>
<td>Growth arrest and apoptosis</td>
<td>Observed principally in cultured cancer cells exposed directly to PSP-containing preparations.</td>
</tr>
<tr>
<td>6</td>
<td>Myeloid and macrophage activation</td>
<td>Indirect ↑ antitumor response</td>
<td>↑ macrophage activation; ↑ reactive nitrogen intermediates and superoxide</td>
<td>Innate immune stimulation</td>
<td>May contribute to host-mediated antitumor activity but excessive extrapolation from animal macrophage studies should be avoided.</td>
</tr>
<tr>
<td>7</td>
<td>ROS-mediated tumor injury</td>
<td>↑ ROS and DNA damage (compound-dependent)</td>
<td>Context-dependent</td>
<td>Oxidative stress and apoptosis</td>
<td>Secondary mechanism. Strong direct ROS evidence exists for isolated constituents such as <i>T. versicolor</i> laccase and should not automatically be attributed to PSK, PSP or whole mushroom.</td>
</tr>
<tr>
<td>8</td>
<td>Gut microbiome modulation</td>
<td>Indirect (context-dependent)</td>
<td>Altered microbial community composition</td>
<td>Prebiotic and immunometabolic modulation</td>
<td>Human randomized evidence demonstrates microbiome effects of orally administered PSP, but the contribution to cancer outcomes remains uncertain.</td>
</tr>
<tr>
<td>9</td>
<td>Chemosensitization and treatment support</td>
<td>↓ recurrence or ↑ treatment efficacy in selected historical clinical settings</td>
<td>Potential preservation of immune function</td>
<td>Adjunctive immunochemotherapy</td>
<td>Clinical evidence is strongest for pharmaceutical PSK combined with chemotherapy, particularly in historical Japanese gastrointestinal-cancer studies.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Context-dependent</td>
<td>Context-dependent</td>
<td>Limits extrapolation</td>
<td>Major constraints include heterogeneous mushroom products, differences between PSK and PSP, limited human PK data, uncertain systemic exposure to directly cytotoxic concentrations, older chemotherapy regimens in many RCTs and limited modern randomized evidence.</td>
</tr>
</tbody>
</table>


Pathway results for Effect on Cancer / Diseased Cells

Total Targets: 0

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag